TITLE

Neoadjuvant chemoradiotherapy for resectable esophageal carcinoma: A meta-analysis

AUTHOR(S)
Hai-Lin Jin; Hong Zhu; Ting-Sheng Ling; Hong-Jie Zhang; Rui-Hua Shi; Grande, Luis; Patti, Marco G.; Beltran, Marcelo A.
PUB. DATE
December 2009
SOURCE
World Journal of Gastroenterology;12/21/2009, Vol. 15 Issue 47, p5983
SOURCE TYPE
Academic Journal
DOC. TYPE
Article
ABSTRACT
AIM: To compare neoadjuvant chemoradiotherapy and surgery with surgery alone for resectable esophageal carcinoma. METHODS: We used MEDLINE and EMBASE databases to identify eligible studies and manual searches were done to ensure no studies were missed. Trial validity assessment was performed and a trial quality score was assigned. RESULTS: Eleven randomized controlled trials (RCTs) including 1308 patients were selected. Neoadjuvant chemoradiotherapy significantly improved the overall survival compared with surgery alone. Odds ratio (OR) [95% confidence interval (CI), P value], expressed as neoadjuvant chemoradiotherapy and surgery vs surgery alone, was 1.28 (1.01-1.64, P = 0.05) for 1-year survival, 1.78 (1.20-2.66, P = 0.004) for 3-year survival, and 1.46 (1.07-1.99, P = 0.02) for 5-year survival. Postoperative mortality increased in patients treated by neoadjuvant chemoradiotherapy (OR: 1.68, 95% CI: 1.03-2.73, P = 0.04), but incidence of postoperative complications was similar in two groups (OR: 1.14, 95% CI: 0.88-1.49, P = 0.32). Neoadjuvant chemoradiotherapy lowered the local-regional cancer recurrence (OR: 0.64, 95% CI: 0.41-0.99, P = 0.04), but incidence of distant cancer recurrence was similar (OR: 0.94, 95% CI: 0.68-1.31, P = 0.73). Histological subgroup analysis indicated that esophageal squamous cell carcinoma did not benefit from neoadjuvant chemoradiotherapy, OR (95% CI, P value) was 1.16 (0.85-1.57, P = 0.34) for 1-year survival, 1.34 (0.98-1.82, P = 0.07) for 3-year survival and 1.41 (0.98-2.02, P = 0.06) for 5-year survival. CONCLUSION: Neoadjuvant chemoradiotherapy can raise the survival rate of patients with esophageal adenocarcinoma.
ACCESSION #
47336375

 

Related Articles

  • Neoadjuvant Chemoradiotherapy Could Improve Survival Outcomes for Esophageal Carcinoma: A Meta-Analysis. Wang, Dong-Bin; Zhang, Xun; Han, Hong-Li; Xu, Yi-Jun; Sun, Da-Qiang; Shi, Zhen-Liang // Digestive Diseases & Sciences;Dec2012, Vol. 57 Issue 12, p3226 

    Background: The effectiveness of neoadjuvant chemoradiotherapy in patients with resectable esophageal carcinoma remains controversial. Aims: The purpose of this study was to assess the effect of neoadjuvant chemoradiotherapy on operable esophageal carcinoma. Methods: We searched PubMed, EMBASE...

  • A Meta-Analysis of Concurrent Chemoradiotherapy for Advanced Esophageal Cancer. Zhu, Li-Li; Yuan, Ling; Wang, Hui; Ye, Lin; Yao, Gui-Ying; Liu, Cui; Sun, Niu-Niu; Li, Xiao-Jing; Zhai, Shi-Cong; Niu, Ling-Juan; Zhang, Jun-Bo; Ji, Hong-Long; Li, Xiu-Min // PLoS ONE;Jun2015, Vol. 10 Issue 6, p1 

    Background: Concurrent chemoradiotherapy is a standard treatment for local advanced esophageal cancer, but the outcomes are controversial. Our goals were to compare the therapeutic effects of concurrent chemoradiotherapy and radiotherapy alone in local advanced esophageal cancer using...

  • Effect of neoadjuvant chemoradiotherapy on prognosis and surgery for esophageal carcinoma. Jin Lv; Xiu-Feng Cao; Bin Zhu; Lv Ji; Lei Tao; Dong-Dong Wang; Herrmann, Eva // World Journal of Gastroenterology;10/21/2009, Vol. 15 Issue 39, p4962 

    AIM: To investigate the role of neoadjuvant chemoradiotherapy in prognosis and surgery for esophageal carcinoma by a meta-analysis. METHODS: PubMed and manual searches were done to identify all published randomized controlled trials (RCTs) that compared neoadjuvant chemoradiotherapy plus surgery...

  • P-0008THE BENEFITS OF NEO-ADJUVANT CHEMORADIOTHERAPY FOR ESOPHAGEAL CANCER, ARE THEY FOR ALL? Gomes, Fabio M.; Ribeiro, Catarina; Costa, Ligia; Oliveira, Sonia; Barata, Pedro; Sousa, Manuel; Custodio, M. Paula; da Luz, Ricardo; Quaresma, Luisa; Esteves, Jorge; Silva, Gualdino; Pina, Filomena; Cabrita, Fernanda; Pupo, Alexandra; Oliveira, Mario; Marques, Mateus; Mareco, Virginia; da Silva, Guedes; Batarda, M. Lurdes; Fradique, Antonio Caldeira // Annals of Oncology;Jun2013, Vol. 24 Issue suppl_4, piv39 

    No abstract available.

  • Role of surgery, radiotherapy and chemotherapy in papillary tumors of the pineal region: a multicenter study. Fauchon, F.; Hasselblatt, M.; Jouvet, A.; Champier, J.; Popovic, M.; Kirollos, R.; Santarius, T.; Amemiya, S.; Kumabe, T.; Frappaz, D.; Lonjon, M.; Fèvre Montange, M.; Vasiljevic, A. // Journal of Neuro-Oncology;Apr2013, Vol. 112 Issue 2, p223 

    Papillary tumor of the pineal region (PTPR), recently described as a distinct clinicopathological entity, can show aggressive biological behavior. The optimal therapeutic approach of PTPR has not been well defined. The role of surgery, radiotherapy, and chemotherapy in the treatment of PTPR was...

  • Effect of Neoadjuvant Chemoradiation and Surgical Technique on Recurrence of Localized Pancreatic Cancer. Katz, Matthew; Wang, Huamin; Balachandran, Aparna; Bhosale, Priya; Crane, Christopher; Wang, Xuemei; Pisters, Peter; Lee, Jeffrey; Vauthey, Jean-Nicolas; Abdalla, Eddie; Wolff, Robert; Abbruzzese, James; Varadhachary, Gauri; Chopin-Laly, Xavier; Charnsangavej, Chusilp; Fleming, Jason // Journal of Gastrointestinal Surgery;Jan2012, Vol. 16 Issue 1, p68 

    Objectives: To determine the influence of neoadjuvant chemoradiation and standardized dissection of the superior mesenteric artery upon the oncologic outcome of patients with localized pancreatic adenocarcinoma. Methods: One hundred ninety-four patients with pancreatic adenocarcinoma who...

  • Indirect Comparison Showed Survival Benefit from Adjuvant Chemoradiotherapy in Completely Resected Gastric Cancer with D2 Lymphadenectomy. Qiong Yang; Ying Wei; Yan-Xian Chen; Si-Wei Zhou; Zhi-Min Jiang; De-Rong Xie // Gastroenterology Research & Practice;2013, p1 

    Background. Little data on directly comparing chemoradiotherapywith observation has yet been published in the setting of adjuvant therapy for resected gastric cancer who underwent D2 lymphadenectomy. The present indirect comparison aims to provide more evidence on comparing the two approaches....

  • Risk factors for locoregional recurrence in patients with resected N1 non-small cell lung cancer: a retrospective study to identify patterns of failure and implications for adjuvant radiotherapy. Chengcheng Fan; Shugeng Gao; Zhouguang Hui; Jun Liang; Jima Lv; Xiaozhen Wang; Jie He; Luhua Wang // Radiation Oncology;2013, Vol. 8 Issue 1, p1 

    Background Meta-analysis of randomized trials has shown that postoperative radiotherapy (PORT) had a detrimental effect on overall survival (OS) in patients with resected N1 non-small cell lung cancer (NSCLC). Conversely, the locoregional recurrence (LR) rate is reported to be high without...

  • Significant efficacies of neoadjuvant and adjuvant chemotherapy for nasopharyngeal carcinoma by meta-analysis of published literature-based randomized, controlled trials. OuYang, P. Y.; Xie, C.; Mao, Y. P.; Zhang, Y.; Liang, X. X.; Su, Z.; Liu, Q.; Xie, F. Y. // Annals of Oncology;Aug2013, Vol. 24 Issue 8, p2136 

    Background We carried out this meta-analysis to demonstrate efficacies of neoadjuvant chemotherapy (NACT) and adjuvant chemotherapy (AC) for nasopharyngeal carcinoma (NPC) patients based on randomized, controlled trials (RCTs). Patients and methods We comprehensively searched electronic...

Share

Read the Article

Courtesy of VIRGINIA BEACH PUBLIC LIBRARY AND SYSTEM

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics